Oral benfotiamine plus α-lipoic acid normalises complication-causing pathways in type 1 diabetes

Xue-Liang Du, D. Edelstein, M. Brownlee

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Aims/hypothesis: We determined whether fixed doses of benfotiamine in combination with slow-release α-lipoic acid normalise markers of reactive oxygen species-induced pathways of complications in humans. Methods: Male participants with and without type 1 diabetes were studied in the General Clinical Research Centre of the Albert Einstein College of Medicine. Glycaemic status was assessed by measuring baseline values of three different indicators of hyperglycaemia. Intracellular AGE formation, hexosamine pathway activity and prostacyclin synthase activity were measured initially, and after 2 and 4 weeks of treatment. Results: In the nine participants with type 1 diabetes, treatment had no effect on any of the three indicators used to assess hyperglycaemia. However, treatment with benfotiamine plus α-lipoic acid completely normalised increased AGE formation, reduced increased monocyte hexosamine-modified proteins by 40% and normalised the 70% decrease in prostacyclin synthase activity from 1,709±586 pg/ml 6-keto-prostaglandin F to 4,696±533 pg/ml. Conclusions/interpretation: These results show that the previously demonstrated beneficial effects of these agents on complication-causing pathways in rodent models of diabetic complications also occur in humans with type 1 diabetes. Trial registration: NCT00703989. Funding: Juvenile Diabetes Research Foundation grant 8-2003-784 and GCRC grant MO1-RR12248.

Original languageEnglish (US)
Pages (from-to)1930-1932
Number of pages3
JournalDiabetologia
Volume51
Issue number10
DOIs
StatePublished - Oct 2008

Fingerprint

Thioctic Acid
Type 1 Diabetes Mellitus
Hexosamines
Organized Financing
Hyperglycemia
Diabetes Complications
Research
Monocytes
Rodentia
Reactive Oxygen Species
Medicine
benphothiamine
Proteins
prostacyclin synthetase

Keywords

  • Advanced glycation endproducts
  • Benfotiamine
  • Diabetic complications
  • Hexosamine pathway
  • Hyperglycaemia
  • Lipoic acid
  • Prostacyclin synthase
  • Reactive oxygen species
  • Type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Oral benfotiamine plus α-lipoic acid normalises complication-causing pathways in type 1 diabetes. / Du, Xue-Liang; Edelstein, D.; Brownlee, M.

In: Diabetologia, Vol. 51, No. 10, 10.2008, p. 1930-1932.

Research output: Contribution to journalArticle

@article{bcb802a42a374e858e985f5fb6c7f683,
title = "Oral benfotiamine plus α-lipoic acid normalises complication-causing pathways in type 1 diabetes",
abstract = "Aims/hypothesis: We determined whether fixed doses of benfotiamine in combination with slow-release α-lipoic acid normalise markers of reactive oxygen species-induced pathways of complications in humans. Methods: Male participants with and without type 1 diabetes were studied in the General Clinical Research Centre of the Albert Einstein College of Medicine. Glycaemic status was assessed by measuring baseline values of three different indicators of hyperglycaemia. Intracellular AGE formation, hexosamine pathway activity and prostacyclin synthase activity were measured initially, and after 2 and 4 weeks of treatment. Results: In the nine participants with type 1 diabetes, treatment had no effect on any of the three indicators used to assess hyperglycaemia. However, treatment with benfotiamine plus α-lipoic acid completely normalised increased AGE formation, reduced increased monocyte hexosamine-modified proteins by 40{\%} and normalised the 70{\%} decrease in prostacyclin synthase activity from 1,709±586 pg/ml 6-keto-prostaglandin F1α to 4,696±533 pg/ml. Conclusions/interpretation: These results show that the previously demonstrated beneficial effects of these agents on complication-causing pathways in rodent models of diabetic complications also occur in humans with type 1 diabetes. Trial registration: NCT00703989. Funding: Juvenile Diabetes Research Foundation grant 8-2003-784 and GCRC grant MO1-RR12248.",
keywords = "Advanced glycation endproducts, Benfotiamine, Diabetic complications, Hexosamine pathway, Hyperglycaemia, Lipoic acid, Prostacyclin synthase, Reactive oxygen species, Type 1 diabetes",
author = "Xue-Liang Du and D. Edelstein and M. Brownlee",
year = "2008",
month = "10",
doi = "10.1007/s00125-008-1100-2",
language = "English (US)",
volume = "51",
pages = "1930--1932",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Oral benfotiamine plus α-lipoic acid normalises complication-causing pathways in type 1 diabetes

AU - Du, Xue-Liang

AU - Edelstein, D.

AU - Brownlee, M.

PY - 2008/10

Y1 - 2008/10

N2 - Aims/hypothesis: We determined whether fixed doses of benfotiamine in combination with slow-release α-lipoic acid normalise markers of reactive oxygen species-induced pathways of complications in humans. Methods: Male participants with and without type 1 diabetes were studied in the General Clinical Research Centre of the Albert Einstein College of Medicine. Glycaemic status was assessed by measuring baseline values of three different indicators of hyperglycaemia. Intracellular AGE formation, hexosamine pathway activity and prostacyclin synthase activity were measured initially, and after 2 and 4 weeks of treatment. Results: In the nine participants with type 1 diabetes, treatment had no effect on any of the three indicators used to assess hyperglycaemia. However, treatment with benfotiamine plus α-lipoic acid completely normalised increased AGE formation, reduced increased monocyte hexosamine-modified proteins by 40% and normalised the 70% decrease in prostacyclin synthase activity from 1,709±586 pg/ml 6-keto-prostaglandin F1α to 4,696±533 pg/ml. Conclusions/interpretation: These results show that the previously demonstrated beneficial effects of these agents on complication-causing pathways in rodent models of diabetic complications also occur in humans with type 1 diabetes. Trial registration: NCT00703989. Funding: Juvenile Diabetes Research Foundation grant 8-2003-784 and GCRC grant MO1-RR12248.

AB - Aims/hypothesis: We determined whether fixed doses of benfotiamine in combination with slow-release α-lipoic acid normalise markers of reactive oxygen species-induced pathways of complications in humans. Methods: Male participants with and without type 1 diabetes were studied in the General Clinical Research Centre of the Albert Einstein College of Medicine. Glycaemic status was assessed by measuring baseline values of three different indicators of hyperglycaemia. Intracellular AGE formation, hexosamine pathway activity and prostacyclin synthase activity were measured initially, and after 2 and 4 weeks of treatment. Results: In the nine participants with type 1 diabetes, treatment had no effect on any of the three indicators used to assess hyperglycaemia. However, treatment with benfotiamine plus α-lipoic acid completely normalised increased AGE formation, reduced increased monocyte hexosamine-modified proteins by 40% and normalised the 70% decrease in prostacyclin synthase activity from 1,709±586 pg/ml 6-keto-prostaglandin F1α to 4,696±533 pg/ml. Conclusions/interpretation: These results show that the previously demonstrated beneficial effects of these agents on complication-causing pathways in rodent models of diabetic complications also occur in humans with type 1 diabetes. Trial registration: NCT00703989. Funding: Juvenile Diabetes Research Foundation grant 8-2003-784 and GCRC grant MO1-RR12248.

KW - Advanced glycation endproducts

KW - Benfotiamine

KW - Diabetic complications

KW - Hexosamine pathway

KW - Hyperglycaemia

KW - Lipoic acid

KW - Prostacyclin synthase

KW - Reactive oxygen species

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=51249107520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51249107520&partnerID=8YFLogxK

U2 - 10.1007/s00125-008-1100-2

DO - 10.1007/s00125-008-1100-2

M3 - Article

C2 - 18663426

AN - SCOPUS:51249107520

VL - 51

SP - 1930

EP - 1932

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 10

ER -